Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy
ChiCTR2200064256Phase 4Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of olanzapine in postoperative nausea and vomiting (PONV), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Frequency and severity of postoperative nausea and vomiting within 24 hours. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
olanzapine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2200064256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064256.